Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07716124

Use of AlignRT System During Stereotactic Radiosurgery

Conditions: Brain Metastases

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 20
Sponsor: Institute of Oncology Ljubljana

Location: Institute of Oncology Ljubljana Ljubljana

Summary

This prospective study evaluated whether the AlignRT surface-guided radiotherapy system improves patient positioning accuracy during stereotactic radiosurgery (SRS) for brain metastases compared with standard manual positioning. Twenty adults scheduled for single-fraction SRS were positioned twice before treatment. Participants were first positioned using the standard manual method with delta couch shift and were then positioned automatically using the AlignRT system. After each positioning method, a partial cone-beam computed tomography (CBCT) scan was performed to measure residual setup deviations in three translational and three rotational directions. The primary objective was to compare the average setup deviations between the two positioning methods and determine whether AlignRT provided more accurate patient positioning. The additional positioning and imaging procedure prolonged the treatment visit by up to 15 minutes and involved a low additional imaging dose.

Eligibility Criteria

Inclusion Criteria: * Adults aged 18 years or older * Patients with brain metastases eligible for single-fraction stereotactic radiosurgery * Treatment performed using the TrueBeam STx linear accelerator * Able and willing to provide written informed consent. Exclusion Criteria: * Patients younger than 18 years * Patients receiving fractionated stereotactic radiotherapy * Treatment performed using a linear accelerator other than TrueBeam STx.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07716124). StuddyBuddy aggregates publicly available trial information.